Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2019-11-13 Regulatory Filings
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Trading Halt 3 pages 448.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from HeraMED Limited regarding a trading halt requested by the company pending an upcoming announcement. It references ASX Listing Rule 17.1 and includes a formal letter requesting the halt. There is no financial data, report content, or detailed analysis present. The document is short (2792 characters) and serves as a notification about the trading halt rather than a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2019-11-13 English
Response to ASX Price and Volume Query 4 pages 617.7KB
Regulatory Filings Classification · 95% confidence The document is a letter from the Australian Securities Exchange (ASX) to HeraMED Limited regarding a Price and Volume Query. It requests information about unusual trading activity and compliance with continuous disclosure obligations under ASX Listing Rules 3.1 and 3.1A. The letter includes HeraMED's response confirming no undisclosed information and compliance with listing rules. This is a regulatory compliance communication related to market disclosure and trading activity, not a financial report, earnings release, or management discussion. It is a formal regulatory filing responding to a market query, fitting the category of Regulatory Filings (RNS). The document length (8899 characters) and content confirm it is not a brief announcement or a full report but a detailed regulatory response letter.
2019-11-13 English
Hapvida Saude (Brazil) Trial Update 2 pages 259.2KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 7 November 2019 providing an update on a trial of HeraMED's medical technology solutions with Hapvida Saude in Brazil. It discusses the deployment and usage of the HeraBEAT and HeraCARE Pro solutions in hospitals and clinics, trial progress, feedback received, and ongoing discussions for broader rollout. The content is focused on operational updates and business progress rather than financial results, regulatory filings, or detailed financial reports. The document length is 4498 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication of financial statements, audit information, management changes, or voting results. The nature of the content fits best with a Capital/Financing Update (CAP) as it relates to business development and trial progress of company products, which can impact company valuation and financing considerations. It is not a report publication announcement or regulatory filing as it contains substantive operational information. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-11-06 English
Appendix 3B 15 pages 547.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including unlisted options, shares, terms of securities, issue prices, and shareholder approvals. It references ASX rules and compliance, and includes sections on quotation of securities and agreements related to listing. The content is focused on announcing and detailing a new issue of securities rather than reporting financial results or management commentary. It is a formal announcement of capital raising activities and securities issuance, consistent with the Capital/Financing Update category. The document length is substantial and contains detailed issuance data, not just a brief notice or link to a report, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-11-04 English
September Quarter Activities Report and Appendix 4C 8 pages 434.8KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 30 October 2019 providing a quarterly update on HeraMED's business activities and financial position for the three months ending 30 September 2019 (Q3 CY2019). It includes operational highlights, strategic partnerships, market expansion, and a detailed financial overview including cash flow statements. The presence of the Appendix 4C Quarterly report, which is a regulatory requirement under ASX Listing Rule 4.7B for quarterly cash flow reporting, confirms this is a quarterly report. The document contains substantive financial data such as cash flows from operating, investing, and financing activities, cash balances, and payments to directors, which are typical of an Interim/Quarterly Report. It is not merely an announcement of a report or a certification, but a comprehensive quarterly financial and operational update. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2019
2019-10-29 English
Market entry for HeraBEAT and HeraCARE Progresses in India 3 pages 452.5KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 25 October 2019 from HeraMED Limited regarding progress in market entry for their products HeraBEAT and HeraCARE in India. It discusses a second purchase order, extension of a Memorandum of Understanding (MOU), and plans for pilot trials and beta testing. The content is focused on business development, partnerships, and product launch updates rather than financial results, regulatory filings, or detailed financial data. There is no indication of financial statements, audit information, or management discussion of financial results. The document is a corporate announcement about business progress and partnerships, which fits best under the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, or more broadly business development updates. However, since it is about market entry and order receipt (which can be considered a commercial update), and no direct financing or capital structure change is mentioned, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other specific categories. The document is not a report publication announcement (RPA) because it is not announcing the release of a report, nor is it a financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2019-10-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.